Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal Pharmaceuticals has informed the stock exchanges that its trading window will be closed for designated persons and their immediate relatives from October 1, 2025, until 48 hours after the company declares its Un-Audited Financial Results for the quarter and half year ended September 30, 2025. This closure is mandatory under SEBI's Prohibition of Insider Trading Regulations, 2015, and applies to insiders who may have access to unpublished financial information. The company has not yet announced the date of the board meeting where these Q2/H1 FY26 results will be approved, stating it will be communicated separately. Designated persons are barred from buying, selling, or dealing in the company's shares during this blackout period.
This is a routine regulatory filing and does not directly affect retail shareholders. However, it signals that the company's Q2 and half-yearly results are due soon, which could be a catalyst for stock movement once announced. Retail investors should watch for the upcoming board meeting intimation and results declaration date.